# Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC

Source: https://onco.cc/trials/nct07646639/  
OnCo record `nct07646639` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by The First Affiliated Hospital with Nanjing Medical University, now recruiting.

## Summary

Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC is a phase 2, randomised interventional study registered as NCT07646639 by The First Affiliated Hospital with Nanjing Medical University, with a registry enrolment figure of 122 participants, started 2026-05-20 and due to reach its primary completion in 2028-12-31. Interventions recorded: Sintilimab + IL-2 Combined with CAPOX; Short-course low-dose radiotherapy; Short-course standard-dose radiotherapy. Conditions listed: Rectal Cancer; Radiotherapy. Primary outcome: Complete remission. Colorectal eligibility wording from the registry: "Histologically confirmed rectal adenocarcinoma with the distal margin of the tumor located within 12 cm of the anal verge". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: PRIDE-02
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07646639
- Phase: 2
- Setting: Different-Dose Short-Course Radiotherapy Plus CAPOX, Anti-PD-1 Antibody and Interleukin-2 for Locally Advanced Rectal Cancer: A Single-Centre, Prospective, Randomised Phase II Trial
- Sponsor: The First Affiliated Hospital with Nanjing Medical University
- Enrolled: 122

## Sources

- ClinicalTrials.gov NCT07646639: https://clinicaltrials.gov/study/NCT07646639

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07646639.json